Aurobindo Pharma Limited (AUROPHARMA.BO)
INR 1264.95
(1.37%)
INR 1264.95
(1.37%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 61.78 Billion INR | 46.19% |
| 2022 | 40.09 Billion INR | -13.55% |
| 2021 | 45.79 Billion INR | -14.04% |
| 2020 | 85.28 Billion INR | 9.28% |
| 2019 | 48.84 Billion INR | 22.44% |
| 2018 | 39.19 Billion INR | 3.35% |
| 2017 | 38.73 Billion INR | 8.9% |
| 2016 | 35.5 Billion INR | 10.25% |
| 2015 | 33.93 Billion INR | 22.5% |
| 2014 | 26.6 Billion INR | 32.61% |
| 2013 | 21.55 Billion INR | 154.49% |
| 2012 | 8.71 Billion INR | 88.86% |
| 2011 | 2.43 Billion INR | -60.35% |
| 2010 | 10.14 Billion INR | 7.94% |
| 2009 | 9.69 Billion INR | 241.24% |
| 2008 | 2.84 Billion INR | -38.5% |
| 2007 | 4.61 Billion INR | 17.68% |
| 2006 | 3.92 Billion INR | 86.79% |
| 2005 | 2.39 Billion INR | 58.13% |
| 2004 | 1.32 Billion INR | -48.22% |
| 2003 | 2.56 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 16.19 Billion INR | 9.14% |
| 2023 Q3 | 17.61 Billion INR | 12.8% |
| 2023 Q1 | 12.64 Billion INR | 11.89% |
| 2023 Q2 | 15.61 Billion INR | 23.44% |
| 2023 FY | - INR | 46.19% |
| 2023 Q4 | 16.87 Billion INR | -4.21% |
| 2022 Q3 | 10.46 Billion INR | 23.59% |
| 2022 Q2 | 8.46 Billion INR | -12.99% |
| 2022 Q1 | 9.73 Billion INR | 0.92% |
| 2022 FY | - INR | -13.55% |
| 2022 Q4 | 11.3 Billion INR | 8.02% |
| 2021 Q1 | 13.1 Billion INR | -2.46% |
| 2021 Q4 | 9.64 Billion INR | -10.23% |
| 2021 Q3 | 10.74 Billion INR | -15.57% |
| 2021 FY | - INR | -14.04% |
| 2021 Q2 | 12.72 Billion INR | -2.9% |
| 2020 FY | - INR | 9.28% |
| 2020 Q3 | 14.87 Billion INR | 1.47% |
| 2020 Q2 | 14.66 Billion INR | 7.72% |
| 2020 Q1 | 13.6 Billion INR | 0.41% |
| 2020 Q4 | 13.43 Billion INR | -9.69% |
| 2019 Q2 | 11.6 Billion INR | -0.51% |
| 2019 Q4 | 13.55 Billion INR | 9.45% |
| 2019 FY | - INR | 22.44% |
| 2019 Q1 | 11.66 Billion INR | 5.9% |
| 2019 Q3 | 12.38 Billion INR | 6.67% |
| 2018 Q2 | 10.12 Billion INR | 34.11% |
| 2018 Q4 | 11.01 Billion INR | -4.42% |
| 2018 FY | - INR | 3.35% |
| 2018 Q1 | 7.55 Billion INR | -9.29% |
| 2018 Q3 | 11.52 Billion INR | 13.83% |
| 2017 Q3 | 10.58 Billion INR | -6.17% |
| 2017 FY | - INR | 8.9% |
| 2017 Q4 | 8.32 Billion INR | -21.37% |
| 2017 Q2 | 11.28 Billion INR | 31.6% |
| 2017 Q1 | 8.57 Billion INR | 12.27% |
| 2016 Q4 | 7.63 Billion INR | -17.13% |
| 2016 Q1 | 9.12 Billion INR | 1.7% |
| 2016 FY | - INR | 10.25% |
| 2016 Q2 | 9.57 Billion INR | 4.89% |
| 2016 Q3 | 9.21 Billion INR | -3.73% |
| 2015 FY | - INR | 22.5% |
| 2015 Q4 | 8.97 Billion INR | 6.92% |
| 2015 Q3 | 8.39 Billion INR | 12.31% |
| 2015 Q2 | 7.47 Billion INR | 0.46% |
| 2015 Q1 | 7.43 Billion INR | 2.78% |
| 2014 Q3 | 6.27 Billion INR | 0.87% |
| 2014 Q4 | 7.23 Billion INR | 15.26% |
| 2014 FY | - INR | 32.61% |
| 2014 Q1 | 6.7 Billion INR | -19.27% |
| 2014 Q2 | 6.22 Billion INR | -7.15% |
| 2013 Q3 | 6.49 Billion INR | 73.11% |
| 2013 FY | - INR | 154.49% |
| 2013 Q2 | 3.75 Billion INR | 169.48% |
| 2013 Q1 | 1.39 Billion INR | -50.66% |
| 2013 Q4 | 8.3 Billion INR | 27.86% |
| 2012 Q3 | 1.91 Billion INR | -48.91% |
| 2012 Q2 | 3.74 Billion INR | 680.86% |
| 2012 Q4 | 2.82 Billion INR | 47.44% |
| 2012 FY | - INR | 88.86% |
| 2012 Q1 | -644.8 Million INR | -125.79% |
| 2011 Q3 | 518.9 Million INR | 0.0% |
| 2011 FY | - INR | -60.35% |
| 2011 Q4 | 2.5 Billion INR | 381.83% |
| 2010 FY | - INR | 7.94% |
| 2009 FY | - INR | 241.24% |
| 2008 FY | - INR | -38.5% |
| 2007 FY | - INR | 17.68% |
| 2006 FY | - INR | 86.79% |
| 2005 FY | - INR | 58.13% |
| 2004 FY | - INR | -48.22% |
| 2003 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Ajanta Pharma Limited | 12.56 Billion INR | -391.729% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -8952.639% |
| Sigachi Industries Limited | 883.39 Million INR | -6894.322% |
| Bal Pharma Limited | 345.59 Million INR | -17778.799% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | -800.481% |
| Medico Remedies Limited | 150.37 Million INR | -40988.258% |
| Lasa Supergenerics Limited | -65.08 Million INR | 95041.149% |
| Venus Remedies Limited | 711.8 Million INR | -8580.474% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 1755.944% |
| Alpa Laboratories Limited | 86.12 Million INR | -71640.221% |
| Nectar Lifesciences Limited | 1.56 Billion INR | -3851.151% |
| Shilpa Medicare Limited | 2.58 Billion INR | -2287.485% |
| Aarti Drugs Limited | 3.24 Billion INR | -1801.962% |
| Lupin Limited | 36.96 Billion INR | -67.132% |
| Zydus Lifesciences Limited | 56.22 Billion INR | -9.9% |
| Windlas Biotech Limited | 781.72 Million INR | -7804.071% |
| Suven Life Sciences Limited | -992.78 Million INR | 6323.705% |
| Eris Lifesciences Limited | 6.98 Billion INR | -784.393% |
| Valiant Laboratories Limited | 12.73 Million INR | -484927.867% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | -561.906% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 2289.578% |
| Ipca Laboratories Limited | 13.29 Billion INR | -364.587% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -4077.583% |
| Achyut Healthcare Limited | 524 Thousand INR | -11791445.802% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 55.344% |
| Bajaj HealthCare Limited | 444.51 Million INR | -13799.995% |
| RPG Life Sciences Limited | 1.28 Billion INR | -4721.514% |
| Mankind Pharma Limited | 28.09 Billion INR | -119.927% |
| Laurus Labs Limited | 8 Billion INR | -671.767% |
| Piramal Pharma Limited | 13.05 Billion INR | -373.273% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -14260.015% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | -76.487% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | -542.504% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | -444.687% |
| Unichem Laboratories Limited | 742.35 Million INR | -8223.19% |
| Sequent Scientific Limited | 549.8 Million INR | -11138.214% |
| Novartis India Limited | 1.26 Billion INR | -4767.856% |
| Wanbury Limited | 985.49 Million INR | -6169.744% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | -1221.045% |
| Wockhardt Limited | 1.08 Billion INR | -5621.083% |
| Themis Medicare Limited | 562.6 Million INR | -10882.391% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -19002.115% |
| Jubilant Pharmova Limited | 8 Billion INR | -671.767% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | -800.317% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 30.005% |
| Divi's Laboratories Limited | 25.43 Billion INR | -142.972% |
| NATCO Pharma Limited | 18.79 Billion INR | -228.745% |
| Gufic Biosciences Limited | 1.48 Billion INR | -4073.474% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -2270.433% |
| Ind-Swift Limited | 1.06 Billion INR | -5701.302% |
| Procter & Gamble Health Limited | 3.01 Billion INR | -1949.751% |
| FDC Limited | 4.4 Billion INR | -1303.727% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 74788.675% |
| Granules India Limited | 8.6 Billion INR | -618.143% |
| Medicamen Biotech Limited | 245.66 Million INR | -25051.714% |
| Alkem Laboratories Limited | 24.19 Billion INR | -155.373% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -2521.678% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -472933.992% |
| Brooks Laboratories Limited | 41.72 Million INR | -147972.517% |
| Megasoft Limited | 284.73 Million INR | -21600.377% |
| ZIM Laboratories Limited | 462.09 Million INR | -13271.154% |
| Strides Pharma Science Limited | 3.76 Billion INR | -1541.247% |
| Neuland Laboratories Limited | 4.74 Billion INR | -1201.291% |
| Morepen Laboratories Limited | 1.72 Billion INR | -3479.916% |
| Hikal Limited | 2.69 Billion INR | -2195.038% |
| Indoco Remedies Limited | 2.64 Billion INR | -2234.206% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | -1480.483% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -21396.982% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -35218.155% |
| Hester Biosciences Limited | 539.47 Million INR | -11353.408% |